Luba Greenwood, JD

INNOVATION COUNCIL MEMBER
Chief Executive Officer, Board Chair and Co-Founder, Gallop Oncology

Managing Partner and Founder, Dana-Farber Cancer Institute venture capital firm, Binney Street Capital

Chief Executive Officer and Board Chair, Kojin Therapeutics (fmr)

Lecturer, Harvard University

Luba Greenwood is a distinguished executive, investor, and company builder with over 20 years of leadership across biotechnology, healthcare and deep tech, with extensive global board experience.

She has served as CEO of multiple biotechnology companies, including currently serving as CEO, co-founder, and Chair of Gallop Oncology and most recently as CEO and Board Chair of Kojin Tx. She founded and served as Managing Partner of the Dana Farber Cancer Institute’s venture fund, Binney Street Capital, leading transformative investments across therapeutics, diagnostics, and tech-bio. She is also entrepreneur-in residence at PureTech where she plays a key role in PureTech’s oncology and immunology programs. Ms. Greenwood has a proven track record of building world-class teams of scientists, clinicians and companies.

Ms. Greenwood has held senior leadership roles at major tech and pharmaceutical companies, including Google (Verily) and Roche, where as VP of Global Business Development and M&A, she led diagnostics BD and established the East Coast Innovation Hub. Luba has led $15B+ in deals and investments across multiple therapeutic areas, diagnostics, life sciences and tech sectors globally. Her invaluable contributions to the healthcare industry have earned her recognition as a thought leader and advisor to CEOs of leading academic centers worldwide, including DFCI and Wyss Center for Bio and Neuroengineering in Geneva. She is a Thought Leader for the New England Journal of Medicine Catalyst and serves on Investor Committee for the National Cancer Institute. A former litigator at WilmerHale, she is an expert in regulatory, securities, IP, and corporate governance matters, and has lectured at Harvard University’s School of Engineering and Applied Sciences.

Ms. Greenwood has extensive board experience globally and serves on public and private boards, across multiple industries, including healthcare and tech, and has successfully contributed to the growth and profitability of numerous organizations, bringing her operational, industry, and financing expertise. She has served as Chair of the board as well as on the Compensation, Audit, and Nomination committees of a number of companies including In8Bio (INAB), Abcam (ABCAM), where she has spearheaded the sale to Danaher (DHR), Traws Pharma (TRAW), Canadian tech company, BenchSci, Swiss-based Stalicla, UK-based Closed Loop Medicine, as well as Kojin, Gallop Oncology, and non-profit, MassBio. She has a proven track record of building world class teams and companies, building SABs with renown scientists and industry leaders, driving digital transformation and AI initiatives, guiding companies through M&A, complex business development transactions, financing, and organizational change and scaling. With a strong understanding of board dynamics and corporate governance best practices, and as a former lawyer, she has also guided organizations through compliance, activist actions, and human resources challenges. She is a champion for diversity in STEM, and was recognized with the Science Club for Girls Catalyst Award.